chr2-47801125-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000179.3(MSH6):c.3142C>T(p.Gln1048*) variant causes a stop gained change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000179.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 34
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:3
This pathogenic variant is denoted MSH6 c.3142C>T at the cDNA level and p.Gln1048Ter (Q1048X) at the protein level. The substitution creates a nonsense variant, changing a Glutamine to a premature stop codon (CAG>TAG). This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. This variant has been reported in at least one individual with colorectal cancer and one with endometrial cancer whose tumors showed loss of MSH6 via mismatch repair immunohistochemistry (Talseth-Palmer 2010, Buchanan 2014). Based on currently available evidence, we consider this variant to be pathogenic. -
- -
The MSH6 c.3142C>T (p.Gln1048*) variant causes the premature termination of MSH6 protein synthesis. This variant has been reported in the published literature in individuals with colorectal cancer and in an individual with endometrial cancer where immunohistochemistry analysis of the tumors showed loss of MSH6 protein (PMIDs: 20487569 (2010), 23733757 (2013), and 24323032 (2014)). This variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Based on the available information, this variant is classified as pathogenic. -
Lynch syndrome 5 Pathogenic:2
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
- -
Lynch syndrome Pathogenic:1
The MSH6 p.Gln1048X variant was identified in two individuals or families with Lynch syndrome related cancers (Buchanan 2014, Talseth-Palmer 2010); tumours from affected individuals with the variant were shown to be MSH6 deficient by immunohistochemistry. The variant was also identified in the HGMD and the ClinVar database (classified as a pathogenic variant by GeneDx). The p.Gln1048X variant leads to a premature stop codon at position 1048, which is predicted to lead to a truncated or absent protein and loss of function. Loss of function variants of the MSH6 gene are an established mechanism of disease in Lynch syndrome and this is the type of variant expected to cause the disorder. In summary, based on the above information, this variant meets our laboratory’s criteria to be classified as pathogenic. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Gln1048*) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with MSH6-related conditions. ClinVar contains an entry for this variant (Variation ID: 127580). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.Q1048* pathogenic mutation (also known as c.3142C>T), located in coding exon 4 of the MSH6 gene, results from a C to T substitution at nucleotide position 3142. This changes the amino acid from a glutamine to a stop codon within coding exon 4. This mutation has been reported in multiple individuals with personal and/or family histories of colorectal cancer, and tumor studies have shown microsatellite instability and/or loss of MSH6 protein by immunohistochemistry associated with this mutation (Talseth-Palmer BA et al. Hered Cancer Clin Pract, 2010 May;8:5; Ward RL et al. J. Clin. Oncol. 2013 Jul;31:2554-62; Buchanan DD et al. J. Clin. Oncol. 2014 Jan;32:90-100). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at